Impact of Diabetes, Drug-Induced Liver Injury, and Sepsis on Outcomes in Metabolic Dysfunction Associated Fatty Liver Disease-Related Acute-on-Chronic Liver Failure
Ashish Kumar,Anil Arora,Ashok Choudhury,Vinod Arora,Mohamed Rela,Dinesh Kumar Jothimani,Mamun A Mahtab,Harshad Devarbhavi,Chundamanni E Eapen,Ashish Goel,Cesar Yaghi,Qin Ning,Tao Chen,Jidong Jia,Duan Zhongping,Saeed S Hamid,Amna S Butt,Wasim Jafri,Akash Shukla,Seok S Tan,Dong J Kim,Anoop Saraya,Jinhua Hu,Ajit Sood,Omesh Goyal,Vandana Midha,Girish K Pati,Ayaskant Singh,Guan H Lee,Sombat Treeprasertsuk,Kessarin Thanapirom,Ameet Mandot,Ravikiran Maghade,Rinaldi C Lesmana,Hasmik Ghazinyan,Virukalpatti G Mohan Prasad,Abdul K Dokmeci,Jose D Sollano,Zaigham Abbas,Ananta Shrestha,George K Lau,Diana A Payawal,Gamal E Shiha,Ajay Duseja,Sunil Taneja,Nipun Verma,Padaki N Rao,Anand V Kulkarni,Fazal Karim,Vivek A Saraswat,Shahinul Alam,Debashis Chowdhury,Chandan K Kedarisetty,Sanjiv Saigal,Praveen Sharma,Ghulam N Yattoo,Abraham Koshy,Ajay K Patwa,Mohamed Elbasiony,Pravin M Rathi,Sudhir Maharshi,Vishwa M Dayal,Ashish K Jha,Kemal F Kalista,Rino A Gani,Man F Yuen,Virendra Singh,Violeta A Sargsyan,Chien H Huang,Saurabh S Mukewar,Shaojie Xin,Ruveena B Rajaram,Charles Panackel,Sunil Dadhich,Sanjeev Sachdeva,Ajay Kumar,Sanatan Behera,Lubna Kamani,Hemamala V Saithanyamurthi,Babita Prasad,Shiv K Sarin,APASL ACLF Research Consortium (AARC) for APASL ACLF Working Party
DOI: https://doi.org/10.14309/ajg.0000000000002951
2024-07-17
Abstract:Introduction: The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) and its complication, MAFLD-related acute-on-chronic liver failure (MAFLD-ACLF), is rising. Yet, factors determining patient outcomes in MAFLD-ACLF remain understudied. Methods: Patients with MAFLD-ACLF were recruited from the Asian Pacific Association for the Study of the Liver-ACLF Research Consortium (AARC registry). The diagnosis of MAFLD-ACLF was made when the treating unit had identified the etiology of chronic liver disease as MAFLD (or previous nomenclature such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, or non-alcoholic steatohepatitis-cirrhosis). Patients with coexisting other etiologies of chronic liver disease (such as alcohol, hepatitis B virus, hepatitis C virus, etc.) were excluded. Data were randomly split into derivation (n = 258) and validation (n = 111) cohorts at a 70:30 ratio. The primary outcome was 90-day mortality. Only the baseline clinical, laboratory features and severity scores were considered. Results: The derivation group had 258 patients; 60% were male, with a mean age of 53. Diabetes was noted in 27% and hypertension in 29%. The dominant precipitants included viral hepatitis (hepatitis A virus and hepatitis E virus, 32%), drug-induced injury (drug-induced liver injury, 29%), and sepsis (23%). Model for End-Stage Liver Disease-Sodium (MELD-Na) and AARC scores on admission averaged 32 ± 6 and 10.4 ± 1.9. At 90 days, 51% survived. Nonviral precipitant, diabetes, bilirubin, international normalized ratio, and encephalopathy were independent factors influencing mortality. Adding diabetes and precipitant to MELD-Na and AARC scores, the novel MAFLD-MELD-Na score (+12 for diabetes, +12 for nonviral precipitant), and MAFLD-AARC score (+5 for each) were formed. These outperformed the standard scores in both cohorts. Discussion: Almost half of patients with MAFLD-ACLF die within 90 days. Diabetes and nonviral precipitants such as drug-induced liver injury and sepsis lead to adverse outcomes. The new MAFLD-MELD-Na and MAFLD-AARC scores provide reliable 90-day mortality predictions for patients with MAFLD-ACLF.